| Solution Information | help | |
| Enzyme: | Core protein | |
| inhibitor: | BDBM40991 | |
| substrate: | n/a | |
| Solution Type: | Aqueous | |
| pH at Preparation: | n/a | |
| Temp. Prep.: | n/a | |
| Comments: | Assay Overview: The purpose of this biochemical assay is to determine dose response curves for test compounds identified as active in a previous set of experiments entitled, "TR-FRET-based biochemical high-throughput confirmation assay for inhibitors of Hepatitis C Virus (HCV) core protein dimerization" (AID 2152). In this assay, test compounds are incubated with N-terminally tagged GST-core106 and Flag-core106 peptides, followed by addition of a Europium cryptate-tagged anti-GST antibody and a XL-665-tagged anti-Flag antibody. Dimerization of the core106 peptides and subsequent antibody binding brings the antibody tags into close proximity, allowing FRET from the Europium donor to the XL-665 acceptor, resulting in an increase in well FRET. As designed, compounds that inhibit core106 dimerization will prevent the interaction of the tagged antibodies and energy transfer from Europium to XL-665, leading to inhibition of well FRET. Compounds were tested in quadruplicate in a 10-point 1: | |
| If you find an error in this entry please send us an E-mail | ||